Outlook Therapeutics, Inc. financial data

Symbol
OTLK on Nasdaq
Location
111 S. Wood Avenue, Unit #100, Iselin, NJ
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 55.7 % -31.8%
Debt-to-equity -145 % +10.6%
Return On Equity 90 % -38.6%
Return On Assets -199 % +15.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 44.4M shares +87.8%
Common Stock, Shares, Outstanding 43.5M shares +85.8%
Entity Public Float 180M USD +0.5%
Common Stock, Value, Issued 435K USD +85.8%
Weighted Average Number of Shares Outstanding, Basic 37M shares +59.1%
Weighted Average Number of Shares Outstanding, Diluted 37M shares +45.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.51M USD
Research and Development Expense 33.7M USD -1.34%
General and Administrative Expense 38.6M USD +49.9%
Operating Income (Loss) -72.6M USD -18.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -20.2M USD -145%
Income Tax Expense (Benefit) 2.8K USD 0%
Net Income (Loss) Attributable to Parent -43.4M USD +53.8%
Earnings Per Share, Basic 1 USD/shares -129%
Earnings Per Share, Diluted 4 USD/shares +38.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 8.9M USD -72.2%
Accounts Receivable, after Allowance for Credit Loss, Current 1.75M USD
Inventory, Net 4.13M USD
Assets, Current 21.1M USD -53.8%
Operating Lease, Right-of-Use Asset 238K USD -16.8%
Other Assets, Noncurrent 464K USD -3.1%
Assets 22.4M USD -52.5%
Accounts Payable, Current 10.3M USD +84.8%
Employee-related Liabilities, Current 1.93M USD +116%
Accrued Liabilities, Current 5.31M USD +98.2%
Liabilities, Current 31.5M USD -26%
Operating Lease, Liability, Noncurrent 204K USD -21.6%
Liabilities 59.6M USD -54.4%
Retained Earnings (Accumulated Deficit) -592M USD -7.91%
Stockholders' Equity Attributable to Parent -37.2M USD +55.6%
Liabilities and Equity 22.4M USD -52.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11M USD +15.8%
Net Cash Provided by (Used in) Financing Activities 1.74M USD
Common Stock, Shares Authorized 260M shares +333%
Common Stock, Shares, Issued 43.5M shares +85.8%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.22M USD +29.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 8.9M USD -72.2%
Deferred Tax Assets, Valuation Allowance 139M USD +15.9%
Deferred Tax Assets, Gross 139M USD +16%
Operating Lease, Liability 261K USD -10.8%
Lessee, Operating Lease, Liability, to be Paid 315K USD -15.9%
Operating Lease, Liability, Current 56.6K USD +77.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 81.8K USD +2.33%
Lessee, Operating Lease, Liability, to be Paid, Year One 80K USD +2.39%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 54.3K USD -34.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 83.7K USD +2.28%
Deferred Tax Assets, Operating Loss Carryforwards 103M USD +10.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.86M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 49.4K USD -40.9%
Operating Lease, Payments 19.3K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 77.2K USD +949%
Share-based Payment Arrangement, Expense 8.45M USD +57.4%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%